Novo Nordisk A/S (NYSE:NVO) Shares Sold by Avior Wealth Management LLC

Avior Wealth Management LLC decreased its position in shares of Novo Nordisk A/S (NYSE:NVO) by 3.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 14,755 shares of the company’s stock after selling 567 shares during the quarter. Avior Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $1,526,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Wealth Alliance lifted its position in Novo Nordisk A/S by 2.7% in the fourth quarter. Wealth Alliance now owns 11,836 shares of the company’s stock valued at $1,224,000 after buying an additional 313 shares during the last quarter. First American Trust FSB lifted its position in Novo Nordisk A/S by 6.1% in the fourth quarter. First American Trust FSB now owns 50,229 shares of the company’s stock valued at $5,196,000 after buying an additional 2,868 shares during the last quarter. Private Client Services LLC acquired a new position in Novo Nordisk A/S in the fourth quarter valued at about $381,000. Keel Point LLC lifted its position in Novo Nordisk A/S by 7.8% in the fourth quarter. Keel Point LLC now owns 6,724 shares of the company’s stock valued at $696,000 after buying an additional 489 shares during the last quarter. Finally, Bison Wealth LLC lifted its position in Novo Nordisk A/S by 27.1% in the fourth quarter. Bison Wealth LLC now owns 7,571 shares of the company’s stock valued at $783,000 after buying an additional 1,613 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Down 0.4 %

Shares of NYSE:NVO opened at $123.45 on Wednesday. The firm’s 50-day moving average is $126.16 and its two-hundred day moving average is $110.32. The company has a debt-to-equity ratio of 0.19, a current ratio of 0.82 and a quick ratio of 0.64. Novo Nordisk A/S has a 1 year low of $75.56 and a 1 year high of $138.28. The firm has a market capitalization of $553.99 billion, a PE ratio of 45.72, a price-to-earnings-growth ratio of 2.06 and a beta of 0.41.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share for the quarter, topping analysts’ consensus estimates of $0.66 by $0.05. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. The firm had revenue of $9.51 billion for the quarter, compared to analyst estimates of $9.14 billion. Analysts predict that Novo Nordisk A/S will post 3.33 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Shareholders of record on Monday, March 25th were paid a $0.664 dividend. This is a positive change from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. This represents a yield of 0.9%. The ex-dividend date of this dividend was Friday, March 22nd. Novo Nordisk A/S’s dividend payout ratio is currently 48.89%.

Analyst Ratings Changes

A number of research analysts have commented on the stock. BMO Capital Markets assumed coverage on shares of Novo Nordisk A/S in a research report on Friday, April 12th. They issued an “outperform” rating and a $163.00 target price on the stock. UBS Group assumed coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 16th. They issued a “neutral” rating on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Monday, April 1st. Finally, Morgan Stanley assumed coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 price target on the stock. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $133.60.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.